22 May 2026
EMA/CVMP/104787/2026
Committee for Veterinary Medicinal Products

Summary of opinion[1] (initial authorisation)

Nobivac NXT HC

Common name: Feline calicivirosis and feline viral rhinotracheitis vaccine (live)

On 21 May 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a marketing authorisation for the veterinary medicinal product Nobivac NXT HC, lyophilisate and solvent for suspension for injection, intended for cats. The applicant for this veterinary medicinal product is Intervet International B.V.

Nobivac NXT HC is an immunological veterinary medicinal product containing live feline herpesvirus 1, strain G2620A, and live feline calicivirus, strain F9 (ATCvet code QI06AD03) as the active substance, which stimulates active immunity against feline calicivirus and feline herpesvirus type 1 (also known as feline rhinotracheitis virus) in cats.

The benefits of Nobivac NXT HC: The vaccine will be part of a new range of vaccines for felines, Nobivac NXT. Efficacy has been established in pre-clinical studies conducted to an acceptable standard involving experimental infections. The following efficacy claims were considered acceptable: reduction of mortality, clinical signs and virus excretion caused by infection with feline herpesvirus type 1 (FHV) and reduction of clinical signs and virus excretion caused by infection with feline calicivirus (FCV). Nobivac NXT HC thus increases the range of available vaccines for cats.

The most common side effects are injection site swelling, 0.5 – 2 cm in diameter, lasting for 1 day, and elevated temperature, ≥ 39.7 °C, lasting for 1 day.

The full indication is: Active immunisation of cats to reduce mortality, clinical signs and virus excretion caused by infection with feline herpesvirus (FHV) type 1 (feline rhinotracheitis virus), and to reduce clinical signs and virus excretion caused by infection with feline calicivirus (FCV). Onset of immunity is 1 week, and duration of immunity for FHV type 1 and FCV is 1 year after primary vaccination and 3 years after revaccination.

Detailed conditions for the use of this product are described in the summary of product characteristics

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

(SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Nobivac NXT HC and therefore recommends the granting of the marketing authorisation.